Results 31 to 40 of about 45,745 (258)

The immunogenicity of human-origin therapeutic antibodies are associated with V gene usage

open access: yesFrontiers in Immunology, 2023
Therapeutic antibodies can elicit unwanted immune responses in a subset of patients, which leads to the production of anti-drug antibodies (ADA).
Zicheng Hu   +2 more
doaj   +1 more source

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

open access: yes, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald   +29 more
core   +1 more source

Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses

open access: yes, 2022
International audienceThe multiple mechanisms of action of antiviral monoclonal antibodies (mAbs) have made these molecules a potential therapeutic alternative for treating severe viral infections. In addition to their direct effect on viral propagation,
Mireia Pelegrin   +9 more
core   +1 more source

Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm [PDF]

open access: yes, 2011
Background Antibody-fluorophore conjugates are invaluable reagents used in contemporary molecular cell biology for imaging, cell sorting and tracking intracellular events.
Durvasula, Ravi V.   +26 more
core   +1 more source

H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier

open access: yesFrontiers in Aging Neuroscience
BackgroundTherapeutic monoclonal antibodies (mAbs) show great promise for treating neurological disorders thanks to their high selectivity and potency. However, their clinical potential is significantly limited by poor penetration across the blood-brain ...
Ziwei Yuan   +5 more
doaj   +1 more source

Therapeutic Antibodies in Multiple Sclerosis [PDF]

open access: yesNeurodegenerative Diseases, 2007
ment of ever more effective drugs for the treatment of MS. The first immunomodulatory agents to benefit from the development mentioned above, interferon(Avonex , Betaferon/Betaseron , Rebif ) and glatiramer acetate (Copaxone ), have been on the market for more than a decade now and are established, safe, yet only mildly effective treatments for MS ...
Goebels, Norbert, Becher, Burkhard
openaire   +3 more sources

Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]

open access: yes, 2011
Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N.   +5 more
core   +1 more source

Helix matrix-enhanced transformer model for high-accuracy Raman identification of biological products

open access: yesResults in Chemistry
The identification of biological products, such as vaccines, blood components and recombinant therapeutic proteins, involve diverse challenges. This study introduces a novel method that employs Raman spectroscopy with a transformer model enhanced by ...
Jin Ling   +4 more
doaj   +1 more source

A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice

open access: yesBiomedicines, 2022
Human metapneumovirus (HMPV) and human respiratory virus (HRSV) are two leading causes of acute respiratory tract infection in young children. While there is no licensed drug against HMPV, the monoclonal antibody (mAb) Palivizumab is approved against ...
Hugues Fausther-Bovendo   +9 more
doaj   +1 more source

Editorial: Effector functions of therapeutic antibodies

open access: yes, 2022
Therapeutic antibodies are broadly used in both oncology and autoimmune indications. Currently there are more than hundred antibodies approved by the FDA and many more are in development.
Peipp, Matthias   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy